Legal Representation
Attorney
Paul C. Llewellyn
USPTO Deadlines
Next Deadline
1232 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2022-12-06)
Due Date
December 06, 2028
Grace Period Ends
June 06, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
39 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 6, 2022 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Dec 6, 2022 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Nov 3, 2022 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Nov 2, 2022 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Nov 1, 2022 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Oct 31, 2022 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Oct 14, 2022 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Oct 14, 2022 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Sep 9, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Sep 7, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Sep 7, 2022 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Sep 7, 2022 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Mar 5, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Mar 3, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 3, 2022 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Mar 3, 2022 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Sep 14, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Sep 12, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Sep 12, 2021 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Sep 12, 2021 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Mar 10, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Mar 8, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 8, 2021 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Mar 8, 2021 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Sep 15, 2020 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jul 21, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jul 21, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jul 1, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jun 16, 2020 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jun 13, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jun 12, 2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jun 12, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jun 3, 2020 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jun 3, 2020 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jun 3, 2020 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jun 3, 2020 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Mar 18, 2020 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Mar 17, 2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 14, 2020 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Gene therapies for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Viruses, viral vectors and viral constructs for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases
First Use Anywhere:
Sep 19, 2016
First Use in Commerce:
Sep 19, 2016
Additional Information
Design Mark
The mark consists of an abstract representation of the DNA double helix structure in maroon and gold.
Color Claim
The color(s) maroon and gold is/are claimed as a feature of the mark.
Classification
International Classes
005